Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36350989.
- Also identified by DOI 10.1126/scitranslmed.abo3605.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice.
Medical subject headings
- Tumor Microenvironment
- Neoplasms